Pershing Edward - 26 Aug 2026 Form 4 Insider Report for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)

Reporting relationship: CEO, Director, 10%+ Owner
Issuer ticker: PVCT
Reported as of: 26 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Aug 2026, 14:20:29 UTC
Prior SEC filing: 02 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Ed Pershing

Key filing fact

Pershing Edward filed Form 4 for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) on 26 Aug 2026.

Key facts

This page summarizes Pershing Edward's Form 4 filing for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 26 Aug 2026, 14:20.

Change

Previous filing in this sequence was filed on 02 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001689739 Primary reporting owner

Pershing Edward

Relationship: CEO, Director, 10%+ Owner
Address: 800 S. GAY STREET,, SUITE 1610, KNOXVILLE
Signature: /s/ Ed Pershing
Signature date: 26 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PVCT transaction Derivative

8% Unsecured Convertible Promissory Note

Options Exercise

Transaction value
Shares
Change %
Price
Shares after: $840,000
Date: 26 Aug 2026
Ownership: Direct
Underlying class: Series D-1 Convertible Preferred Stock
Underlying amount: 11,328
Exercise price: $2.86
Footnotes: F3, F4, F6

PVCT transaction Derivative

Series D-1 Convertible Preferred Stock

Options Exercise

Transaction value
Shares: +11,328
Change %: +0.39%
Price: $0.000000^*
Shares after: 2,924,949
Date: 26 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 113,280
Exercise price
Footnotes: F1, F2, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").

Footnote F2

The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

Footnote F3

The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing.

Footnote F4

On August 26, 2026, the 2025 Note converted into 11,328 shares of Series D-1 Preferred Stock.

Footnote F5

The amount reported reflects an adjustment to correct a typographical error in a previously filed Form 4. This adjustment does not reflect a transaction by the Reporting Person.

Footnote F6

The amount reported reflects an adjustment to correct a typographical error in a previously filed Form 4. This adjustment does not reflect a transaction by the Reporting Person.